Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
    • Transcripts
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Nora AI
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team

You seem to be using a wider screen, would you like to enable a wider viewing experience on this page?

ExpreS2ion Biotechnologies – Presentation of year-end report 2023

By HC Andersen Capital
ExpreS2ion Biotech Holding

You can already now sign up for the event and send in your questions. You don’t have to participate live to send in questions for the event.

ExpreS2ion Biotechnologies will release its 2023 year-end results on 8 February 2024. Later the same day at 10:00, ExpreS2ion Biotechnologies’ CFO Keith Alexander will take a deeper dive into the results and achievements in a virtual live event.

During 2023, ExpreS2ion Biotechnologies announced a review of its strategy, pipeline, and organization to further advance in the company’s exploratory pipeline and technology platforms. In Q4 2023, we saw the new strategy being carried out with the company together with partners being awarded a grant to obtain clinical proof-of-concept of a Nipah virus (NiV) vaccine candidate. This is a first strong signal of the new strategy direction that will leverage their platform to advance assets with shorter development timelines and less costly paths to value creation. Besides the recent quarter's financial results and a look into 2024, we expect that the attention in the event could be directed towards the progress in its strategy chance.

ExpreS2ion Biotechnologies is a Danish pharmaceutical company, which focuses on the development of vaccines through the use of its non-viral Drosophila S2 cells-based expression system.

Disclaimer: HC Andersen Capital receives payment from ExpreS2ion Biotechnologies for a Corporate Visibility/Digital IR subscription agreement. /Michael Friis 11.15 23 January 2024.

Recent videos

Scanfil press conference
23.01.2026 klo 14.00 Scanfil
Admicom, Webcast, Q4'25
21.01.2026 klo 10.00 Admicom
GomSpace - Strategic direction & Q&A
19.01.2026 klo 15.00 GomSpace Group
Oncopeptides, Audiocast, Investor Conference, 2026
16.01.2026 klo 10.00 Oncopeptides
Duell, Webcast, Q1'26
14.01.2026 klo 10.30 Duell
View all videos
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.